Wefel, Jeffrey S.
Ryan, Charles J.
Van, Julie
Jackson, James C.
Morgans, Alicia K.
Funding for this research was provided by:
bayer healthcare
Article History
Accepted: 7 March 2022
First Online: 6 May 2022
Change Date: 28 November 2022
Change Type: Update
Change Details: A peer-reviewed Video Abstract was retrospectively added to this publication
Declarations
:
: Bayer HealthCare Pharmaceuticals, Inc. (Whippany, NJ, USA) provided funding, in line with GPP3 guidelines, for medical writing support from Rebecca Hopkins, BSc, and editorial assistance from Annabel Ola, MSc, of Scion (London, UK) in the development of the initial draft and for medical writing and editorial support from Sara Black, ISMPP CMPP™, of OPEN Health Communications (London, UK) for formatting for journal submission and addressing reviewer comments. The authors retain ultimate responsibility for opinions, conclusions, and data interpretation.
: JSW has acted as a consultant for Angiochem, Bayer, Juno, Novocure, Vanquish Oncology, and Magnolia Tejas, and has been an advisory board member for AbbVie, Bayer, Blueprint Medicines, and Magnolia Neurosciences. CJR has received honoraria from Janssen, Bayer, and Sanofi Aventis. JV and JJ declare no conflicts of interest. AKM has received honoraria from AstraZeneca, Astellas, Bayer, Clovis, Dedreon, Myovant, Pfizer, Novartis, Blue Earth, Janssen, Sanofi, Genentech, and Seattle Genetics, and has received research support from Bayer, Astellas, and Seattle Genetics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors made substantial contributions to the conception and planning of this review, to the analysis and interpretation of the literature search results, and to the drafting and revision of this manuscript. All authors approved the final submitted version of the manuscript.